Regeneron to seek EUA for lower dose of Covid-19 mAb cocktail as new trial shows major drop in risk of hospitalization or death
The success of monoclonal antibody (mAb) cocktails in keeping people with Covid-19 out of the hospital continued Tuesday, with Regeneron announcing that even a lower …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.